Lapatinib Ditosylate Monohydrate Chemical Structure (Tykerb Spl Graphic 01)
Tykerb Tablet
Product Images NDC 0078-0671
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tykerb (NDC 0078-0671). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Tykerb Spl Graphic 02)
Figure 2 (Tykerb Spl Graphic 03)
Figure 3 (Tykerb Spl Graphic 04)
Bottle Label (Tykerb Spl Graphic 05)
This is a description of a medication package. The medication is lapatinib, which comes in tablet form with each tablet containing 358 mg of lapatinib ditoylte, equivalent to 250 mlapati. The recommended dosage is not provided, and users should refer to the prescribing information. The medication should be stored at temperatures between 20°C and 25°C, with excursions permitted between 15°C and 30°C. The package includes 150 tablets distributed by Novartis Pharmaceuticals Corp, located in New Jersey, USA. The product has a unique identifier code, NDC 0078-0671-19. It also includes instructions for healthcare professionals to use safety closures.*
Tykerb Spl Graphic 06
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
